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Abstract
A population of more than six million people worldwide at high risk of Alzheimer’s disease (AD) are those with Down
Syndrome (DS, caused by trisomy 21 (T21)), 70% of whom develop dementia during lifetime, caused by an extra copy of β-
amyloid-(Aβ)-precursor-protein gene. We report AD-like pathology in cerebral organoids grown in vitro from non-
invasively sampled strands of hair from 71% of DS donors. The pathology consisted of extracellular diffuse and fibrillar Aβ
deposits, hyperphosphorylated/pathologically conformed Tau, and premature neuronal loss. Presence/absence of AD-like
pathology was donor-specific (reproducible between individual organoids/iPSC lines/experiments). Pathology could be
triggered in pathology-negative T21 organoids by CRISPR/Cas9-mediated elimination of the third copy of chromosome 21
gene BACE2, but prevented by combined chemical β and γ-secretase inhibition. We found that T21 organoids secrete
increased proportions of Aβ-preventing (Aβ1–19) and Aβ-degradation products (Aβ1–20 and Aβ1–34). We show these
profiles mirror in cerebrospinal fluid of people with DS. We demonstrate that this protective mechanism is mediated by
BACE2-trisomy and cross-inhibited by clinically trialled BACE1 inhibitors. Combined, our data prove the physiological role
of BACE2 as a dose-sensitive AD-suppressor gene, potentially explaining the dementia delay in ~30% of people with DS.
We also show that DS cerebral organoids could be explored as pre-morbid AD-risk population detector and a system for
hypothesis-free drug screens as well as identification of natural suppressor genes for neurodegenerative diseases.
Introduction
Production [1–3], and degradation [4] of β-amyloid peptides
(Aβ) are among the central processes in the pathogenesis of
Alzheimer’s disease (AD). The canonical Aβ peptide is
produced after sequential cleavage of the β-amyloid pre-
cursor-protein (APP) by β-secretase and γ-secretase, gen-
erating a peptide that most often begins 99 amino acids (aa)
from the C-terminus of APP with Asp1 and contains the
next 37–42 aa of the APP sequence, generating a range of
peptides (Aβ1–37, 38, 39, 40, and 42). The longer of these
peptides can be detected in toxic amyloid aggregates in the
brain, associated with AD and other neurodegenerative
disorders [5]. As APP gene is located on human
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chromosome 21, people with Down Syndrome (DS, caused
by trisomy 21 (T21)) are born with one extra copy of this
gene, which increases their risk of developing AD. Non-DS
(euploid) people inheriting triplication of the APP gene
alone (DupAPP) develop AD symptoms by age 60 with
100% penetrance. Paradoxically, only ~70% of people with
DS develop clinical dementia by age 60, suggesting the
presence of other unknown chromosome 21-located genes
that modulate the age of dementia onset [6, 7]. A number of
secretases participate in the physiological cleavage of APP
[1, 8], generating various peptides involved in neuronal
pathology. BACE1 is the main β-secretase in the brain [9],
whereas the expression and function of its homologue
BACE2 (encoded by a chromosome 21 gene) remain less
clear [10, 11]. At least three different activities of BACE2
were recorded with regards to APP processing: as an aux-
iliary β-secretase (pro-amyloidogenic), as a θ-secretase
(degrading the β-CTF and preventing the formation of
Aβ), and as Aβ-degrading protease (AβDP) (degrading
synthetic Aβ-peptides at extremely acidic pH). It remains
unclear which of these activities reflect the role of BACE2
in AD. The potential activity of BACE2 as an anti-
amyloidogenic θ-secretase can be predicted from studies on
a variety of transfected cell lines that overexpress APP, and
artificially manipulate the dose of BACE2 [12–15]. These
studies uncovered that BACE2 can cleave the product of β-
secretase (APP β-CTF) between aa19 and aa20, generating
a 1–19 fragment [13–15], thereby potentially preventing the
formation of amyloidogenic Aβ, and degrading the β-CTF
that has been implicated in neuronal toxicity, and impair-
ment of several neuronal functions, such as axonal transport
and autophagy [16]. When offered synthetic Aβ40/42 pep-
tides in solution, purified BACE2 protein can rapidly
degrade them by cutting after aa20 and aa34, to generate the
1–20 and 1–34 peptide products, but only at very acidic pH
(3.5–4). In this reaction, BACE2 is 150-fold more efficient
Fig. 1 Aβ peptide profiles secreted by trisomy 21 cerebral orga-
noids. a Using Aβ IP-MS spectra from organoid (see Supplemen-
tary Figs. 1, 2, 4) conditioned media (CM), ratios were calculated of
areas under the peak between the non-amyloidogenic and amyloido-
genic peptides within a single mass-spectrogram. IP-MS spectra were
produced for three timepoints (four timepoints in exp3) for each iPSC-
derived organoid line, in each of three independent experiments (each
experiment starting at the point of undifferentiated iPSC). The team
performing the IP-MS analysis was blinded to the genotypes in all
experiments. BACE2-AβDP (clearance) products= [1–20 & 1–34],
total BACE2= [1–19 & 1–20 & 1–34], amyloidogenic peptides=
[1–38 & 1–39 & 1–40 & 1–42], α-site products= [1–16 & 1–17]. Exp1
and Exp2 p values: Holm–Bonferroni sequential corrections (α= 0.05)
of two-tailed student t test comparisons. Exp3: Holm-corrected p values
after one-way ANOVA. Error bars: standard error. Combined data for
the isogenic iPSC lines for all three experiments passed the
Holm–Bonferroni correction (α= 0.05) of sequential two-tailed student
t test comparisons of each peptide ratio shown in Fig. 1a (available on
request). T21 and D21: isogenic iPCS derived from a single mosaic
individual with DS published previously (Murray A et al. 2015), QM-
DS1 and QM-DS2: unrelated DS iPSC, DupAPP: FEOAD iPSC. b All
three experiments in Fig. 1a were combined to calculate the ratios of
BACE2-related non-amyloidogenic peptides (1–19 or 1–34) to
BACE2-unrelated non-amyloidogenic peptides (1–16 or 1–17) in
organoid CM. Holm-corrected p values after one-way ANOVA are
shown. Error bars: standard error. c Same ratios as in part ‘a’ were
calculated on IP-MS spectra obtained from cerebrospinal fluid samples
of people with DS (n= 17) and age-matched normal controls (n= 12).
Data are presented as mean ±1SD.
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than BACE1, which is also capable of this cleavage, upon
conditions of increased enzyme concentration/time [12, 14].
Neither of these two putative anti-amyloidogenic actions of
BACE2 (the θ-secretase activity, generating aa1–19, or the
Aβ-degrading protease activity (AβDP or Aβ clearance)
generating aa1–20 and aa1–34), have yet been demon-
strated to be the functional role of BACE2 under physio-
logically fluctuating gene doses in vivo in the human brain.
A naturally occurring form of gene overdose for both APP
and BACE2 is DS, caused by the trisomy of human chro-
mosome 21 (T21) that harbours both APP and BACE2
genes. As increased levels of soluble Aβ were observed
already in foetal brains in DS [17], we examined cerebral
organoids grown from induced pluripotent stem cells (iPSC)
generated by non-integrational reprogramming of primary
cells donated by people with DS, including an isogenic DS
(T21) iPSC model [18], as a platform to analyse the T21-
specific effects on APP proteolytic processing.
Results
Trisomy 21 (but not DupAPP) skews the ratios of Aβ
non-amyloidogenic peptides
We compared organoids from isogenic iPSC clones, derived
from the same individual with DS, mosaic for T21 and
normal disomy 21 (D21) cells [18]. Cerebral organoids
were derived following a published protocol [19], and
shown to contain neurons expressing markers of all six
layers of the human cortex (Supplementary Fig. 1) and no
significant difference in the proportions of neurons and
astrocytes between the D21 and T21 organoids (Supple-
mentary Fig. 2). The integrity and copy number of the iPSC
lines were validated at the point of starting the organoid
differentiation, for chromosome 21 (Supplementary Fig. 3),
and the whole genome (available on request). T21/
D21 status was further verified by interphase Fluores-
cence In Situ Hybridization (FISH) on mature organoid
slices, (Supplementary Fig. 4a). The C-terminal region of
APP can be processed by the sequential action of different
proteases to produce a range of protein fragments and
peptide species, including Aβ (Supplementary Fig. 5). Aβ
peptide profiles were analysed from organoid-conditioned
media (CM) whereby each CM sample was taken from a 6
cm dish culturing a pool of 12–16 organoids derived from
one iPSC clone, in total: n= 15 CM samples for Exp1
(three trisomic isogenic clones, two disomic isogenic
clones, three timepoints each), n= 12 CM samples for Exp2
(two trisomic isogenic clones, two disomic isogenic clones,
three timepoints each) and n= 20 CM samples for Exp3
(one trisomic isogenic clone, one disomic isogenic clone,
one DupAPP clone, one line each for two different
unrelated DS individuals, four timepoints each). CM was
collected at timepoints between days 100–137 of culturing
and analysed using immunoprecipitation in combination
with mass spectrometry (IP-MS) [20]. Please see “Methods”
and “Supplementary Data” sections for more detailed
explanations, and statistical controls used for individual
iPSC line-to-line comparisons (Fig. 1a). Relative ratios
were calculated of areas under the peak between the pep-
tides of interest within a single mass spectrum (raw data
example in Supplementary Fig. 6d), therefore unaffected by
the variability in the total cell mass between wells growing
organoids. The proportions of non-amyloidogenic peptides
with the signature of BACE2 cleavage products, both as a
putative θ-secretase (as reflected by the Aβ1–19 product)
and putative AβDP or Aβ-clearance products (Aβ1–20 &
1–34), or combined, (relative to the sum of Aβ amyloido-
genic peptides (Aβ1–38 & 1–39 & 1–40 & 1–42)) were
approximately doubled in CM from T21 organoids, com-
pared with isogenic normal controls, and reached levels of
>80% of the amyloidogenic peptide levels (Fig. 1a). This
result was fully reproduced in three independent experi-
ments, each starting from undifferentiated iPSCs (three
vertical columns of graphs in Fig. 1a). In experiment 3,
more recently generated iPSC lines from different indivi-
duals were introduced; from a euploid patient with FEOAD
caused by DupAPP [21], and from two unrelated people
with DS (Supplementary Figs. 1–3). The 1–34 & 1–20/
amyloidogenic ratios were not significantly different
between D21 and DupAPP lines, suggesting the third copy
of the APP gene alone did not cause any change in this
ratio. Ratios of 1–34 & 1–20/amyloidogenic peptides and
combined BACE2-products/amyloidogenics were sig-
nificantly increased in T21 clones (combining all three T21
individuals) compared with D21 or DupAPP lines (Fig. 1a).
The ratio of 1–19/amyloidogenics was significantly higher
in T21 clones from the isogenic model, compared with its
disomic isogenic control, and compared with DupAPP, but
it was unchanged in the other two unrelated DS iPSC lines
(see also Supplementary Information for a more-detailed
explanation). As the proportions of BACE2-unrelated α-site
cleavage products (1–16, 1–17) were not different between
T21 and isogenic D21 organoids (in any of the three
experiments) (Fig. 1a), it can be predicted that the increased
presence of 1–19, 1–20, and 1–34 peptides in T21 contributes
towards an overall increase in soluble peptides that are non-
amyloidogenic. The validity of this prediction was tested by
an independent biochemical method (ELISA), by measuring
the Aβ-peptide concentrations within the isogenic T21:D21
organoid CM comparison, which showed an increase in
absolute concentrations caused by T21 for each Aβ 1–38,
1–40, and 1–42, with no difference in the Aβ 1–42/1–40 ratio
between T21 and isogenic D21 clones, mirroring the readout
in the absolute levels of IP-MS peaks (Supplementary Fig. 6).
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Analysis of IP-MS area under peak (used in Fig. 1 to calculate
relative ratios) showed a near linear correlation when plotted
against absolute peptide concentrations measured by ELISA,
for each Aβ 1–38, 1–40, and 1–42 (Supplementary Fig. 6),
validating our relative ratio calculations by an independent
biochemical method.
To estimate the contribution of BACE2 towards the anti-
amyloidogenic pathway relative to other anti-amyloidogenic
cleavages at the α-site, we calculated the peptide ratios of
1–19/1–16 or 1–17 (θ secretase/α secretase products) and
1–34/1–16 or 1–17 (BACE2-AβDP/α secretase products).
We observed that T21 organoids produce statistically highly
significant increases in all four of these ratios, relative to
isogenic D21, or non-isogenic DupAPP organoids (Fig. 1b).
Therefore, we conclude that T21 causes these effects in our
organoid system. The D21 ratios were not significantly
different to DupAPP, suggesting that the third copy of genes
other than APP causes these effects. These peptide profiling
data strongly favour the hypothesis of a genetic dose-
sensitive anti-amyloidogenic action of BACE2.
Non-amyloidogenic Aβ peptide ratios mirror
between T21 organoids and DS-CSF
In order to assess if the peptide ratio differences from
Fig. 1b have any relevance in vivo, we analysed the Aβ-
peptide profiles immunoprecipitated from human cere-
brospinal fluid (CSF). We have previously produced IP-MS
data on CSF from people with DS and age-matched controls
[22]. We repeated the calculations shown for organoids in
Fig. 1b, on IP-MS results from CSF samples from DS (n=
17) and age-matched euploid people (n= 12). All four
relative ratio calculations showed an increase in peptide
ratios in CSF from people with DS, compared with age-
matched euploid controls, of which three comparisons were
statistically highly significant (Fig. 1c). This suggests that in
DS brains, the third copy of BACE2 skews the anti-
amyloidogenic processing significantly towards BACE2-
cleavages, relative to other anti-amyloidogenic enzymes
cleaving at the α-site. Importantly, these CSF results vali-
date the in vivo relevance of the peptide ratios obtained
using CM from iPSC-derived cerebral organoids (compar-
ison of Fig. 1b and Fig. 1c).
Aβ-degrading activity of BACE2 is cross-inhibited by
clinically trialed BACE1 inhibitors
Chemical inhibition of BACE1 remains an attractive ther-
apeutic strategy for AD. As BACE2 is a homologous pro-
tein, most inhibitors tested in clinical trials also cross-inhibit
the (pro-amyloidogenic) β-secretase activity of BACE2,
which has been proven as the cause of several unwanted
side-effects, such as skin pigmentation changes. As our data
suggest that the opposite, Aβ-degrading, activity of BACE2
has an important role, we designed a new FRET-based
in vitro assay, in which efficient AβDP-cutting after Aβ
aa34 by BACE2 at pH=3.5 could be measured (Fig. 2),
whereas zero activity by BACE1 was detectable under same
conditions (Supplementary Information). We demonstrated
that at least two BACE1 inhibitor compounds (of which one
recently used in clinical trials) inhibit the AβDP (Aβ-
clearance) activity of BACE2 in a dose-dependent manner
(Fig. 2). This has, to our knowledge, so far not been shown,
and could provide an additional explanation for the failure
of some BACE1 inhibitor clinical trials, and should be
taken in consideration when testing new inhibitors.
AβDP product (Aβx-34) colocalises with BACE2 in
human brain and organoid neurons
As in vitro experiments showed that BACE2 can very
efficiently cleave the Aβ34 site in the FRET peptide (Fig. 2)
Fig. 2 FRET-based assay for BACE2 cleavage. A newly custom
designed FRET reagent (spanning the Aβ34 site) was digested at
pH=3.5 by the human BACE2 in presence or absence of the stated
inhibitors for 2 h. Enzyme activity was defined by measuring the
fluorescence increase before and after the incubation. Blank-subtracted
fluorescence units were normalized to the control digest and a one-way
ANOVA was performed. P values were calculated with a post hoc
Bonferroni multiple comparison (only pairs relative to the untreated
control simultaneously compared). Error bars: standard error. n= 3
replicates per inhibitor per concentration.
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and synthetic Aβ1–40 peptide in solution at an acidic pH
[12], we sought to visualize if the presence of the substrate
(Aβ1–40), enzyme (BACE2), and one of the products of
this reaction (Aβ1–34) can be detected in our organoids, in
a subcellular compartment known to be acidic. First, by
immunofluorescence (IF) using pan-anti-Aβ (4G8), anti-
BACE2, or neo-epitope-specific antibodies against Aβx-40
and Aβx-34 [23], we detected significantly higher signals
(normalized to pan-neuronal marker) in T21 organoid
neurons, compared with isogenic D21 ones (Supplementary
Fig. 4b–d). Pearson’s coefficient showed a high level of
colocalisation (>0.55) of both the main substrate (Aβx-40)
and its putative degradation product (Aβx-34) with BACE2
in neurons of cerebral organoids, in LAMP2+ compartment
(known to be a subset of lyzosomes, therefore low pH
vesicles) (Fig. 3 & Supplementary Fig. 7). In comparison,
the Pearson’s coefficient for BACE1 with Aβx-34 was only
0.16 (Fig. 3 & Supplementary Fig. 7), and its pattern of
subcellular localization was different to BACE2 (high
colocalization with Rab7 and Sortilin, much lower with
LAMP2). Using IF on human brain sections, a similar
highly significant difference was observed (Fig. 4a, b): Aβx-
34 colocalised with BACE2 (0.52 (±0.034 SEM)) as
opposed to BACE1 (0.01 (±0.021 SEM)). The colocalised
signal of Aβx-34 and BACE2 was seen in three categories
of objects (Fig. 4), in all analysed samples: four individual
Fig. 3 Subcellular compartment localisation of Aβ degradation
product Aβx-34 in hiPSC-derived cerebral organoid sections.
Pairwise Pearson’s coefficient of colocalisation for a pair of co-stained
antibodies: Aβx-34, and a specific marker for the subcellular vesicle
compartment: lipid rafts (Flotillin1), lysosomes (LAMP1), macro-
autophagosomes (LC3A), early endosomes (EEA1), macro-
autophagosome-lysosome fusion/exosomes (Sortilin), late endosomes
(Rab7), specific sub-sets of lysosomes (LAMP2, LAMP2A) and
CMA-chaperone (HSC70). In the final two columns of the histogram,
the Pearson’s colocalisation level was shown between Aβx-34 and
BACE1 or BACE2, respectively (repeated in more detail in Supple-
mentary Fig. 7). Greater than 95% of cells in all of these images were
MAP2+ neurons (not shown). Representative images of the organoid
stainings from which the coefficients were calculated are shown in the
panels. Last column in the bottom right panel is the zoomed-in inset
from the previous column. Images were captured using AiryScan Zeiss
confocal microscopy, and single 0.16 μm slices are shown (from 20 μm
full z-stack analysed). Error bars: standard error, p values: after stan-
dard one-way ANOVA using post hoc Bonferroni multiple compar-
ison calculation. Scale bar: 5 μm.
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Fig. 4 Localisation of AβDP degradation products and Aβ peptides
with BACE2 in hippocampal sections of the human post-mortem
brain. a Immunofluorescence analysis of the brain of DS-AD-1 co-
stained for Aβx-34, BACE2, and GFAP. A typical near-circular neuritic
plaque is shown (in which DAPI faintly stains the fibrillar amyloid
deposits). Arrows indicate three categories of objects in which the
colocalisation of BACE2 and the AβDP product Aβx-34 is observed.
White arrows: intraneuronal fine-vesicular pattern; white arrowheads:
large intraneuronal spherical granules (lipofuscin); black arrows with
white arrowheads: amorphous extracellular aggregates. See Methods
and Supplementary Fig. 8 for experiments controlling the extent of
lipofuscin autofluorescence effects. b DS-AD1 brain co-stained for
Aβx-34 and BACE1, or Aβx-40, BACE2 and GFAP, and Pearson’s
coefficient of colocalisation for proteins stained in parts ‘a’ and ‘b’,
with the addition of the staining for Aβx-42 neo-epitope (not shown).
Error bars: SEM. c Same IF staining combinations as in part ‘a’ (except
for GFAP) were used in three additional brain samples: DS-AD-2, 3,
and 4. d Brain sample co-stained for BACE2 and Aβx-34 of a 28 yrs
old person with Down syndrome without dementia, and euploid non-
demented (ND) controls aged 42 and 84. Scale bar: 20 μm.
Fig. 5 CRISPR/SpCas9-HF1-mediated reduction of BACE2 copy
number from three to two in the T21C5 hiPSC line. a BACE2
exon3 sequence with 7 bp deletion (yellow) provoked by the CRISPR/
SpCas9-HF1 is shown. Red: restriction endonuclease HpyCH4IV sites
(a de novo HpyCH4IV site is generated by the 7 bp deletion). b
agarose gel electrophoresis of the 733 bp PCR product containing the
targeted site before (uncut) and after digestion with HpyCH4IV (cut),
for the initial clone 2.5, and its colony-purified sub-clone 2.3.5
(renamed further below as “Δ7”). The 294 bp fragment in 2.3.5 is
reduced to 65% of the wt value (normalized to the 439 bp band), and a
de novo 255 bp fragment appears in CRISPR-targeted line (red
asterisk). c Western blot stained with anti-BACE2 antibody of the
lysates of the iPSC line Δ7 compared with the wt T21C5 iPSC line.
Quantification of the total actin-normalised BACE2 signal showed a
significant reduction in Δ7 compared with T21 unedited line. Error
bars: standard error, p value: student’s t test. d BACE2-AβDP/amy-
loidogenic peptides ratio after IP-MS analysis of CM produced by the
48DIV organoids derived from the iPSC line Δ7 compared with the
T21C5wt control were significantly decreased. Error bars: standard
error, p values: two-tailed t test comparison.
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DS-AD brains (Fig. 4a–c), five euploid sporadic AD subjects
(example in Supplementary Fig. 8a, for complete list of brain
samples see Supplementary Table 1) and (in the fine vesicle
compartment only) in five non-demented control euploid
subjects’ neurons (age 42–84), as well as DS brain from a 28
yr old with no plaques or dementia, (examples in Fig. 4d, for
complete list of brain samples see Supplementary Table 1).
Lambda scanning and Sudan black B stainings were inde-
pendently used to subtract the autofluorescence of lipofuscin
granules (Supplementary Fig. 8f, g). This has proven that the
fine-vesicular pattern and large amorphous extracellular
aggregates are not autofluorescent lipofuscin granules, but real
colocalisations of BACE2 and Aβx-34 (Supplementary Fig. 8).
Colocalised signals of Aβx-34 and BACE2 were particularly
strong in areas surrounding neuritic plaques (Fig. 4a–c).
As AβDP cleavage by BACE2 is efficient only at low
pH, we sought to analyse in more detail the BACE2 and
Aβx-34 colocalisation in highly acidic cellular compart-
ments. For this reason, we co-stained lysosome markers
LAMP1 or LAMP2 with Aβx-34. In addition, macro-
autophagic vacuoles containing Aβ were shown to accu-
mulate in AD distended neurites [24], which is why we also
stained with the macro-autophagosome marker LC3A. As
we further found that Aβx-34 did not colocalise with
LAMP1 or LC3A, but colocalised strongly with LAMP2
(Fig. 3, Supplementary Fig. 7 and Supplementary Infor-
mation), we tested colocalisation with the components of an
alternative autophagy pathway: chaperone-mediated autop-
hagy (CMA), and found a very high level of colocalisation
(Fig. 3).
Fig. 6 CRISPR/SpCas9-HF1-mediated reduction of BACE2 copy
number from three to two in the T21C5 hiPSC line provoked early
AD-like pathology in organoids. a–c Early AD-like pathology was
provoked in 41DIV T21C5Δ7 organoids, but was not detected in
T21C5 parental organoids. a–b Treatment of the T21C5Δ7 with
combined βI-IV (β-sectretase inhibitor) and compound E (γ-secretase
inhibitor) from 20 to 41DIV completely prevented the formation of
extracellular amyloid deposits. Staining with amyloid specific dye
(AmyloGlo) and nuclear dye (DRAQ5). Scale bar 50 μm. c β- and γ-
secretase inhibitor treatment highly significantly reduced the presence
of TG3+ (pathologically conformed Tau) cells in T21C5Δ7 organoids
compared with untreated T21C5Δ7 organoids. Scale bar: 20 μm. Error
bars: SD, ****p < 0.0001. Only statistically significant differences
are shown.
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Trisomy of BACE2 skews non-amyloidogenic Aβ
peptide ratios and suppresses AD-like pathology in
organoids
Using CRISPR/SpCas9-HF1, we eliminated a single copy
of BACE2 in the trisomic iPSC clone C5 (T21C5Δ7, a Δ7 bp
in BACE2 exon3, knocking out one of three copies of the
gene), while maintaining the trisomy of the rest of chro-
mosome 21 (Fig. 5a–c, Supplementary Fig. 9, Supplemen-
tary Information). Total actin-normalised BACE2 signal
showed a 27–34% reduction in Δ7 compared with T21
unedited clone, and no significant difference compared with
D21 control (Fig. 5c, Supplementary Fig. 10). Total protein
level of APP in Δ7 remained at trisomic levels, significantly
increased compared with the disomic control (Supplemen-
tary Fig. 10). The CRISPR-edited iPSCs formed cerebral
organoids expressing markers of all six neuronal layers by
48 days in vitro (DIV) (Supplementary Fig. 9c). The
CRISPR correction of BACE2 gene dose from three to two,
resulted in a significant decrease in levels of putative
BACE2-AβDP (Aβ-clearance) products (1–20 & 1–34), as
well as total BACE2-related non-amyloidogenic peptides
(1–19 & 1–20 & 1–34), relative to amyloidogenic peptides
(Fig. 5d). This pinpoints the triplication of BACE2 as a
likely cause of specific anti-amyloidogenic T21 effects we
observed in Fig. 1a. Furthermore, we used two different
dyes to detect any presence of amyloid deposits (the tradi-
tional Thioflavine S, and a newer, more sensitive dye
AmyloGlo [25]) in organoid sections. Remarkably, elim-
ination of the third BACE2 copy caused the T21 organoids
(that had not shown any overt amyloid deposits at 100DIV,
see T21C5 in Supplementary Fig. 11, top row) to develop
extremely early AD-plaque-like deposits (AmyloGlo+ and
Thioflavine S+) in the cortical part of the organoid by
48DIV (Supplementary Fig. 11, middle row), that pro-
gressed aggressively and became much stronger and denser
by 96 DIV, accompanied by massive cell death (Supple-
mentary Fig. 11, bottom row, Supplementary Fig. 12).
In order to prove that extracellular deposits staining
positively with amyloid dyes really are related to
Fig. 7 Amyloid and Tau pathology are shown with six different
methods in T21C5Δ7 organoids that have BACE2 copy number
reduced from three to two by CRISPR/Cas9. a–d The signal of
amyloid specific antibodies Aβx-40 + Aβx-42 (a, b), or 4G8 (c, d)
colocalising with Thioflavine S in T21C5Δ7 (96DIV) organoids was
drastically increased upon treatment with 87% Formic acid for 10
minutes at RT, proving it contains the insoluble extracellular β-
amyloid deposits. Scale bar: 10 μm. e AT8 (hyperphosphorylated Tau)
positive neurites within plaque-like structure in 48DIV organoids.
Left: the whole organoid slice, scale bar: 500 μm. Right: zoom in on
the plaque-like structure from ‘e’, in the three individual z-slices
(interval between slices, 1 μm; scale bar: 20 μm). f AT8 (hyperpho-
sphorylated Tau) positive neurites in 96DIV organoids. Scale bar: 10
μm. g–j TG3 (conformationally altered Tau) staining of unedited
control T21C5 (100DIV) g, CRISPR-edited T21C5Δ7 (48DIV) with
TG3-positive neurons in 48DIV organoids h, i, and CRISPR-edited
T21C5Δ7 (96DIV) showing many TG3+ neurons with diffuse stain-
ing of extracellularized mal-conformed Tau aggregates j. Scale bar:
50 μm. k–n Gallyas staining of human AD brain k, unedited control
T21C5 (100DIV) l, CRISPR-edited T21C5Δ7 (96DIV) m, n shows
negative staining in parental unedited organoid l and very strong signal
in neurons and plaque-like associated neurites within T21C5Δ7
organoid m, n. Scale bars: 50 μm l, m and 20 μm n and 5 μm k. o
Representative western blot of T21C5 and T21C5Δ7 organoid lysates
stained using antibodies against pathologically conformationally
altered Tau (TG3) or general 3 repeat (3 R) Tau. β-actin was used as a
loading control. Human brain tissue of a 75 year old is shown for
comparison. Comparison of the average values (n= 4) for CRISPR-
edited T21C5Δ7 showed a highly significant relative increase in TG3
compared with unedited (n= 4) T21C5 organoids, as indicated in the
graph, p= 0.0127.
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hyperproduction of Aβ amyloidogenic peptides, we cultured
T21C5Δ7 organoids in media containing high concentra-
tions of β and γ secretase inhibitors. Early T21C5 and
T21C5Δ7 organoids were treated with a combination of β-
secretase inhibitor IV and compound E (γ secretase inhi-
bitor XII) (Supplementary Table 2) from 20DIV to 41DIV
(Fig. 6). Amyloid-like deposits were readily detected with
AmyloGlo in the untreated and vehicle only treated
T21C5Δ7 organoids (Fig. 6b), but were completely absent
from T21C5Δ7 organoids treated with β and γ secretase
inhibitors (Fig. 6b, bottom row). Inhibitor treatment also
significantly reduced the number of neurons expressing
pathologically conformed Tau (TG3-positive cells) in the
T21C5Δ7 compared with untreated controls (Fig. 6c). No
AmyloGlo-positive aggregates or TG3-positive cells were
detected in T21C5 organoids under any treatment condi-
tions at DIV41 (Fig. 6a, c) and were also absent in the same
organoids at DIV100 (Fig. 7g, l, Supplementary Fig. 11).
Also, no obvious deleterious effects of the inhibitors, or
vehicle control, could be seen in early unedited T21C5
organoids.
Further histo-pathological verification showed that
elimination of one copy of BACE2-triggered progressive
accumulation of extracellular deposits that co-stain with
Thioflavine S and antibodies against Aβ, both 4G8 and neo-
epitope specific Aβx-40 & Aβx-42. The antibody signal
intensity in colocalisations with Thioflavine S drastically
increased upon pre-treatment with 87% formic acid
(Fig. 7a–d), proving that the deposits contain insoluble Aβ
material. This is further corroborated by the isolation of
fibrillary material from the detergent-insoluble fraction of
the CRISPR-edited organoid. When viewed by transmission
electron microscopy (TEM) the filaments found exhibited a
straight morphology of <10 nm diameter (Supplementary
Fig. 13a), closely resembling fibrils grown in vitro from
synthetic Aβ1–40 peptide (Supplementary Fig. 13c). Fur-
thermore, neuritic plaque-like features were detected by
IHC co-staining with Gallyas in CRISPR-edited organoids
(Fig. 7m, n), but not their unedited T21 control (Fig. 7l).
Human brain from an AD patient is shown for comparison
stained with Gallyas (Fig. 7k). Tau pathology was also
observed by IHC using the hyperphosphorylated Tau anti-
body AT8 (Fig. 7e, f), and by IF for conformationally
altered Tau (TG3, Fig. 7g–j). The relative increase in the
amount of conformationally altered (pathological) Tau in
CRISPR-edited organoids T21C5Δ7, compared with
Fig. 8 Amyloid-like pathology, staining with AmyloGlo, is shown
in different lines of organoids and Human AD Brain served as
positive control. a Human AD Brain (73 yrs) shows amyloid
plaques in the Entorhinal cortex. b QM-DS6 (DIV100) shows no AD
pathology. c–h QM-DupAPP and QM-DS1, 2, 3, 4, 5 show
AmyloGlo-positive aggregates, similar to human brain. Scale bar:
20 μm. i, j Airyscan analysis of QM-DS3 showing super-resolution
images of AmyloGlo-positive material with fibrillar-like appearance.
Scale bar: 5 μm.
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unedited T21 control organoids, was also independently
confirmed by immunoblotting using TG3 antibody. As
shown in Fig. 7o, the protein material isolated from
T21C5Δ7 organoids produced significantly more
TG3 signal than unedited controls, albeit having a weaker
signal with the general 3R-Tau antibody (consistent with
the observed neuronal loss, Supplementary Fig. 12).
AD-like pathology develops reproducibly in
unedited cerebral organoids from 71% of DS
donors, and it is donor-specific
Our data in Figs. 5–7 show that severing the BACE2 dose
by a third, using CRISPR/Cas9, might tip the balance
against the anti-amyloidogenic activity, and provoke AD-
like pathology. Our data in Fig. 1 suggest that anti-
amyloidogenic activity of BACE2 is gene dose dependent,
and its level varies between individuals, and it has been
previously reported that SNP allelic differences in BACE2
gene correlate with age of dementia onset in DS [26]. We
therefore hypothesized that organoids grown from some
people with DS may develop AD-like pathology without
any CRISPR-Cas9 intervention. We then tested this
hypothesis using iPSC lines from six different individuals
with DS, and one DupAPP patient (Table 1). We detected
amyloid-like aggregates (both diffuse and compact in
appearance) in 5/7 unedited iPSC-derived organoids from
people with DS, and one with DupAPP (Fig. 8). The two
donors whose iPSC-organoids did not show pathology are
(i) the T21 iPSC from our isogenic model (whose clinical
status is unknown) and (ii) QM-DS6, a donor who remains
free from dementia symptoms at age 37 (Table 1). Orga-
noids from another five DS donors, and one DupAPP
patient, (all diagnosed with clinical dementia) all showed
presence of diffuse and compact amyloid-like deposits
(Fig. 8) as well as presence of neuritic plaque-like features
(focal hyperphosphorylated tau (AT8+), conformationally
altered tau (TG3+), and filamentous Tau (AT100+)) within
neuropil neurites within plaque-like circular foci
(Fig. 9a–n). This was corroborated by Gallyas intraneuronal
positivity (Fig. 9o–t). Similarly as for T21C5Δ7, we were
able to isolate fibrillary material from the detergent-
insoluble fraction of QM-DupAPP organoid (Supplemen-
tary Fig. 13b), that on TEM resembled fibrils grown in vitro
from synthetic Aβ1–40 peptide (Supplementary Fig. 13c).
Most importantly: tested individual organoids from one
Fig. 9 Tau pathology, staining with Gallyas, and with three dif-
ferent antibodies (hyperphosphorylated, conformationally altered,
and filamentous Tau) in QM-DupAPP (100DIV) and QM-DS2
(100DIV) organoids. a Scan of whole QM-DS2 organoid section
shows two hyperphosphorylated Tau foci (neuritic plaque-like struc-
tures). Scale bar: 500 μm. b Zoom in on the same foci. Scale bar: 100
μm. c, d AT8-positive neurites in the pathological structure number 1
in two individual z-slices. Scale bar: 20 μm. e, f AT8-positive neurites
in the pathological structure number 2 in two individual z-slices. Scale
bar: 20 μm. g–i AT8-positive neurites in further three pathological foci
found at a different depth, from the same organoid (not shown at lower
magnification). Scale bar: 20 μm. j–m AT100 (filamentous Tau)
positive neurons in the cortical layer of QM-DS2 organoid, partly
showing “ballooned neuron” pathology. Scale bar: 5 μm. n TG3
(conformationally altered Tau) positive cells in the cortical layer of
QM-DS2 organoid. Scale bar: 50 μm. o Scan of whole QM-DS2
organoid section stained with Gallyas. Scale bar: 500 μm. p–r zoom in
on the parts of the same organoid shows strongly Gallyas-positive
individual neurons. Scale bar: 50 μm p 20 μm q, r. s Scan of whole
QM-DupAPP organoid section stained with Gallyas. Scale bar: 500
μm. t Zoom in on the same organoid shows equally strong individual
neurons as in QM-DS2 organoid. Scale bar: 50 μm.
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donor (from multiple iPSC clones and multiple independent
experiments) either all did (DupAPP, QM-DS1-5), or all did
not (isogenic T21, QM-DS6) show AD-like pathology
(Table 1), proving the pathology is donor dependent. This
open possibilities of developing assays for pre-therapy risk-
stratification and individualized drug–response quantitation.
In order to further test the hypothesis that decreasing the
level of BACE2 may provoke some AD-like pathology in
organoids, we artificially decreased the level of BACE2
using shRNA, in the QM-DS6 patient’s iPSCs, that did not
show AD-like pathology. The shRNA succeeded in
decreasing the BACE2 protein level by only 28%, (Sup-
plementary Fig. 14a) similar to the CRISPR correction of
three to two copies shown in Fig. 5. This intervention
indeed provoked early (46DIV) presence of AmyloGlo+
aggregates, and a significant increase in TG3+ neurons
(showing pathologically conformed Tau), (Supplementary
Fig. 14b,c). Therefore, we conclude that correction of the
trisomic over-expression of BACE2 in two different and
independent individuals with DS (one using CRISPR, one
using shRNA) both provoked a similar early AD-like
pathology.
Discussion
Several human brain studies show detectable expression
and β-secretase activity of BACE2, though at much lower
levels than that of BACE1 [27–30]. Chemical inhibition of
β-secretase activity is an attractive therapeutic approach
aimed at reducing the production of Aβ [31–33]. Complete
knockout of Bace1 abolished all β-secretase activity in
mouse neurons, while leaving some degree of β-secretase
activity in astrocytes [34]. This activity was abolished by
the complete knockout of both Bace1 and Bace2, leading to
a hypothesis that a BACE2-driven β-secretase activity in
astrocytes may contribute to accelerate the Aβ-production
and AD pathology in DS [34]. In human brain, the β-
secretase activity of BACE1 correlated positively with the
amount of Aβ, whereas the β-secretase activity of BACE2
did not [27]. On the other hand, SNPs at the BACE2 locus
(and not BACE1) correlate with the age of onset of dementia
in people with DS [26], as well as sporadic LOAD in
euploid people in the Finnish population [35], and a recent
report showed that a de novo intronic deletion within one
allele of BACE2 caused EOAD in a 50-year-old euploid
person [36].
All of the above data implicate that a single allele
alteration in the genetic dose of BACE2 is capable of
affecting the risk of AD dementia, but do not resolve the
question whether BACE2 per se acts predominantly as an
accelerator, or a suppressor of AD pathology. The answer to
this question requires clarification, as most chemical
inhibitors used in clinical trials have dual activity against
BACE1 and BACE2 [32, 37].
The increased ratios of 1–20 & 1–34 (BACE2-AβDP) to
the amyloidogenic and α-site products are among our most
consistent and robust observations in T21 organoid CM and
DS-CSF (Fig. 1b, c). The 1–34 generating cleavage can
only occur after the cuts by both β- and γ-secretases have
released Aβ, because the hidden transmembrane site
between aa34 and aa35 is inaccessible to any proteolytic
enzymes until the soluble Aβ (1–37 to 1–42) molecules are
released from the membrane [12, 13]. Therefore, the Aβ1-
34 species can only be a product of an AβDP activity (a
catabolic degradation or clearance of an already made
Aβ1–37 to 1–42 peptides). Besides BACE2, the only
enzymes with potential to cleave the peptide bond
Leu34–Met35 are BACE1 [12, 14], and extracellular matrix
(ECM) metalloproteinases (MMP2 and MMP9) [38], since
no other Aβ-degrading enzymes (neither IDE, nor NEP, nor
ECE) are known to cleave at this site [39]. BACE1 action is
unlikely to cause the increased ratios we observe, as
BACE1 can only generate this cut in solution at very high
enzyme concentration and after prolonged incubation [12].
To further corroborate this point, we designed a novel
FRET-assay and established the conditions in which
BACE2 can efficiently cleave at Aβ34 site (Fig. 2) in 2
hours, conditions under which BACE1 activity at the
Aβ34 site was undetectable (Supplementary Information).
We also demonstrated that two BACE1 inhibitors (β-
Secretase Inhibitor IV—CAS 797035-11-1 (Calbiochem,
originally a Merck compound)), and LY2886721 (Eli Lilly
compound recently used in clinical trials) both inhibit the
AβDP activity of BACE2 in vitro, whereas the γ–secretase
inhibitor (DAPT) had no effect.
This suggests that the AβDP activity (cutting the peptide
bond Leu34–Met35) has a different enzymatic preference,
conditions, and pH, as compared with the classical β-
secretase cleavage that both BACE1 and BACE2 are cap-
able of. As FRET assays cleaving this classical (before
Asp1) site are generally used to measure the BACE1 inhi-
bitors’ selectivity for BACE1 or BACE2, our data suggest
that the degree of selectivity for any given inhibitor calcu-
lated this way, does not necessarily reflect whether the same
selectivity would apply for their cross-inhibition of the
Leu34–Met35 site cleavage (AβDP) activity. Interestingly,
the presence of the Aβx-34 degradation product, both alone
[23] and colocalising with BACE2 (Fig. 4) show elevated
levels in cells and extracellular aggregates immediately
surrounding neuritic plaques, suggesting BACE2 degrada-
tion of not only newly produced Aβ, but also of Aβ that is
released and re-deposited (from and to) existing deposits. A
recent report on widespread somatic changes in individual
neurons suggests an additional mechanism for the produc-
tion of toxic Aβ species, including products that do not
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require secretase cleavage [40], underscoring the impor-
tance of efficient Aβ degrading mechanisms that protect
from AD, such as the one exerted by BACE2 that we
describe here.
A recent mouse model has shown that introducing a third
dose of chromosome 21 to a mouse that several hundred
fold overexpresses Aβ40 and 42 worsens the amyloid pla-
que load, and this correlates with an unexpected decrease in
the Aβ40/42 ratio [41]. This unfavourable ratio effect (the
cause of which is unknown) is expected to worsen the
plaque load and AD pathology, and a mere 1.5× increase of
Bace2 dose in this mouse model has no chance in protecting
the mouse against a >100× overload of Aβ. In another
mouse model, where transgenic BACE2 was artificially
over-expressed together with transgenic wtAPP, it actually
decreased Aβ40 and 42 to the wt mouse control levels, and
the presence of BACE2 transgene reversed behavioural
pathologies seen in TgAPP mouse [42].
This indicates that a balance of doses of APP and BACE2
affects levels of soluble Aβ40 and 42, and their oligomer-
ization and aggregation as a consequence. Our results in
Figs. 5–7 further corroborate that a significant disturbance of
this balance by a reduction in BACE2 copy number is suf-
ficient to cause an early AD-like pathology in T21 cerebral
organoids. We did not see any amyloid plaque-like structures
at >100DIV organoids from three independent T21 iPSC
clones (or normal disomic clones) of our isogenic system
(Supplementary Figs. 1, 2, 4, 7, 11, 15, Figs. 3, 7, 8). Sur-
prisingly, CRISPR/Cas9 elimination of the third copy
of BACE2 in the same T21 clone caused widespread Amy-
loGlo+ deposits at 41DIV, and widespread neuritic plaque-
like structures with profound neuron loss (Supplementary
Figs. 11, 12) and Tau pathology at 96DIV (Figs. 6, 7).
Our data in Fig. 1 suggest that anti-amyloidogenic activity of
BACE2 is gene dose dependent, and its level varies between
individuals, with SNP allelic differences in BACE2 corre-
lating with age of dementia onset [26]. We therefore hypo-
thesized that organoids grown from some people with DS
may develop AD-like pathology without any CRISPR-Cas9
intervention. Diffuse amyloid plaque-like appearance with
Tau pathology was recently reported in 110 days old cerebral
organoids from only a single clone of a single DS-hiPSC line
[43] so far. We subsequently analysed iPSC-derived orga-
noids at approximately the same cell culture age from a total
of seven different individuals with DS and one with
DupAPP. We found flagrant AD-like pathological changes in
5/7 DS tested (71%), as well as the one DupAPP. Very
interestingly, when this assessment was repeated in inde-
pendent experiments, and when individual organoids from a
single experiment were compared, it was a black/white pic-
ture: either they all had AD-like pathology, or none did,
driven solely by the genotype of the donor (Table 1). Our
data, though not conclusive, are illustrative of the stratifying
potential of this technology. For example, the cerebral
organoids from individual QM-DS3 showed the worst AD-
like pathology with fibrillary amyloid deposits (Fig. 8f, i, j,
Table 1), and this individual was diagnosed with dementia at
age 37. In contrast, organoids from individual QM-DS6
showed no pathology (Fig. 8b, Table 1), and this individual
was also dementia free at age 37. This opens up possibilities
for finding correlations with clinical parameters, for which a
much larger number of individuals would have to be tested.
Concordantly with our hypothesis, when QM-DS6 iPSCs
had their BACE2 level lowered by 28% using an shRNA
construct, this provoked early amyloid and Tau pathology in
otherwise pathology-negative organoids (Supplementary
Fig. 14).
To confirm that the AmyloGlo deposits were in fact
aggregated β-amyloid containing material, early organoids
were treated with a combination of β-secretase inhibitor IV
(βI-IV) and gamma secretase inhibitor XII (Compound E)
(Fig. 6a, b). The combination of these inhibitors should
prevent any production of Aβ, and therefore eliminate
AmyloGlo positivity. After treatment for 21 days, the
inhibitor treatment did indeed prevent the formation of
plaque-like deposits within T21C5Δ7 organoids, confirm-
ing that such deposits are comprised of β-amyloid. The
same treatment conditions also significantly reduced the
number of TG3-positive cells in T21C5Δ7 organoids
(Fig. 6c), highlighting the ability to modulate both amyloid
and tau pathology in the cerebral organoid system. This also
demonstrates the feasibility of using this AD-like organoid
pathology in future hypothesis-free drug screens for che-
mical compounds that may prevent/inhibit amyloid pro-
duction or aggregation.
In view of our results, it becomes inviting to hypothesize
that triplication of BACE2 may be the cause of the delayed
onset of dementia in 30% of people with DS compared with
DupAPP [7], and (because of the predicted abundance of
BACE2 mRNA in endothelial cells) also the cause of a
significantly lower degree of cerebral amyloid angiopathy
(CAA) in the brains of people with DS compared with those
of DupAPP [44]. Our organoid system is not informative in
this regard, as we could not detect any endothelial cells in
our organoids (not shown). This, however, is also an
advantage, as it allows uncovering the mechanisms that are
specific to neurons in the absence of endothelial or blood
cell-derived tissue components.
In neurons, a recent report also found that an increased
APP dose may act (through an unknown mechanism) as a
transcriptional repressor of several chromosome 21 genes,
including BACE2 [45]. This observation needs further
verification and mechanistic explanation, but if true, it
would imply that the protective effect of the third copy of
BACE2 in DS that we observe is actually quenched by the
third copy of APP, which opens up possibilities of
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chemically intervening to inhibit this transcriptional
repression and potentially unleash a much greater degree of
BACE2 protection. An integration of the two observations
(the one in [45] and the one in our report) suggests this
could be exploited as an additional new protective/ther-
apeutic strategy for AD in general.
We found, surprisingly, an equally high or higher level
of colocalisation of Aβx-34 with LAMP2A, as with the
general LAMP2 (Fig. 3). The high level of colocalisation
with LAMP2A and absence of colocalisation with either
LC3A or LAMP1 (Fig. 3) suggest that AβDP activity of
BACE2 that generates Aβ34 is not related to classical
lysosomal degradation or macroautophagy, but rather could
be related to a CMA-like process [46, 47]. The only pub-
lished study that linked CMA with APP processing [48]
found a motif that satisfies the criteria for a CMA-
recognition KFERQ motif at the very C-terminus of APP
(KFFEQ), and this paper demonstrated that C99 (β-CTF)
can bind HSC70. However, paradoxically, when this motif
is deleted from the β-CTF, the binding to HSC70 is not
abolished, but rather increased, suggesting the presence of
another, alternative CMA-recognition motif within the β-
CTF peptide [48]. The association of the AβDP x-34 pro-
duct with LAMP2A/CMA compartment is a provocative
new observation that requires further studies.
In conclusion, we found that relative levels of specific
non-amyloidogenic and AβDP (Aβ-clearance) products are
higher in T21 organoids and DS-CSF, and they respond to
the dose of BACE2 (and not APP). We also demonstrated
that BACE2-AβDP activity generating one of these pro-
ducts can be cross-inhibited in solution by recently clini-
cally tested BACE1 inhibitors. All components of the AβDP
degradation reaction (hitherto only demonstrated in solution
in vitro): the main substrate (Aβx-40), the enzyme
(BACE2), and its putative degradation product (Aβx-34),
we found highly colocalised in discrete intracellular vesicles
in human brain neurons, (and not astrocytes), suggesting
that at least some of the AβDP activity generating Aβx-34
takes place intra-neuronally and physiologically during
lifetime, before the onset of AD pathology, in both normal
and DS brains. Furthermore, we directly demonstrated that
the trisomic level of BACE2 protected T21-hiPSC organoids
from early AD-like amyloid plaque pathology, therefore
proving the physiological role of BACE2 as an AD-
suppressor gene. The BACE2’s θ-secretase anti-amyloido-
genic cleavage and the AβDP degradation actions could
both be contributing to an overall AD-suppressive effect.
Regardless of the contribution of each of these modes of
action, our combined data suggest that increasing the
action of BACE2 could be exploited as a therapeutic/pro-
tective strategy to delay the onset of AD, whereas cross-
inhibition of BACE2-AβDP activity by BACE1 inhibitors
would have the unwanted worsening effects on disease
progression. We also show that cerebral organoids from
genome-unedited iPSCs could be explored as a system for
pre-morbid detection of high-risk population for AD, as




Human subjects were participants in the “The London
Down Syndrome Consortium (LonDownS): an integrated
study of cognition and risk for AD in Down Syndrome”
inter-disciplinary study, enrolled after informed consent, as
per ethical approval 13/WA/0194, IRAS project
ID:120344 see http://www.ucl.ac.uk/london-down-
syndrome-consortium). Dementia diagnostic status was
obtained via carer report and medical records, based on
assessment by the individual’s own clinician. To confirm
diagnoses, we collected detailed data on dementia symp-
toms from the Cambridge Examination for Mental Dis-
orders of Older People with Down’s Syndrome and Others
with Intellectual Disabilities (CAMDEX), a clinical tool
used for diagnosing dementia in individuals with DS. This
was independently reviewed by two psychiatrists. One iPSC
line (QM-DS1) was established from an individual 40 year
old who was diagnosed with dementia aged 40. Consensus
ratings agreed that this individual showed signs of dementia
and died 2 years later following significant decline. AD was
noted as the cause of death. Another line came from an
individual (QM-DS2) who was diagnosed with dementia
aged 63. The sample was taken at age 67 and at this time
point, consensus was that the individual presented with
signs indicative of possible dementia. This individual was
still alive for follow up 2 years later, with a confirmed
diagnosis of AD-dementia and AD-related seizures devel-
oped at age 68. The third line came from an individual
diagnosed with dementia at age 37 (QM-DS3). Another line
came from the individual QM-DS6, who donated hair at age
31, and remains dementia free after follow up at age 37. The
age, sex, ApoE genotype, and dementia status of all other
individuals are detailed in Table 1.
Primary hair follicle keratinocyte sampling
Upon specific informed consent, three to six individual
strands of hair were non-invasively plucked from the scalp
hair of donor subjects, and placed in transport medium
(DMEM (Sigma D5546), 2 mM glutamine (Sigma G7513),
1x Pen/Strep (Sigma, P4333), 10% foetal calf serum). Upon
arrival to the laboratory, hair follicles were placed in col-
lagen coated T25 flasks in KGM2 medium (Lonza
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CC-3107) and incubated at 37 °C, 5% CO2. Primary kera-
tinocyte cultures were split after reaching 35–50% con-
fluency using 0.05% Trypsin/0.02% EDTA.
Reprogramming of primary keratinocytes
Primary keratinocyte cultures were expanded to 70% con-
fluency, electroporated with plasmids encoding reprogram-
ming factors in episomal vectors (non-integrational
reprogramming), and transferred to 0.1% gelatin coated
wells (six-well plate), pre-seeded with mitotically disabled
mouse embryonic fibroblast (MEF) feeder cells. Specifi-
cally, trypsinised 700,000 keratinocytes were washed once
with sterile PBS and electroporated using the Nucleofector
4D (Lonza, X-module apparatus, kit V4XP-3024, pro-
gramme DS138, following manufacturer’s instructions)
with 3 µg of the episomal plasmid mix (equimolar mixture
of plasmids obtained from Addgene: pCE-hOct3/4, pCE-
hSK, pCE-hUL, pCE-mp53DD and pCXB-EBNA1). After
electroporation, cells were transferred from the cuvette to
KGM2 medium (Lonza CC-3103 and CC-4125). Solution
was gently mixed and transferred to the six-well plate with
feeders. On day 2 (48 hours after electroporation) medium
was removed and replaced with fresh KGM2 medium. On
the day 4, the medium was switched to standard human
embryonic stem cell (hESC) medium (high glucose DMEM
with 20% Knockout Serum Replacement, non-essential
amino acids, Glutamax+penstrep (Life Technologies), 2-
mercaptoethanol (100 µM) with 10–20 ng/mL of FGF2).
From day 10 onwards, MEF-CM supplemented with 10–20
ng/mL of FGF2 was used. By day 20, iPSC colonies were
observed. After day 30, large iPSC colonies were
mechanically picked, and expanded using ReLeSR and
hESC medium plus ROCK inhibitor (Y-27632, Stem Cell
Technologies). The iPSC lines were generated in this way
from six unrelated people with DS (QM-DS1, QM-DS2,
QM-DS3, QM-DS4, QM-DS5, and QM-DS6, respectively,
detailed in Table 1). The iPSCs from a 64-year-old euploid
patient with FEOAD caused by DupAPP [21] (QM-
DupAPP) were generated from peripheral blood mono-
nuclear cells, using the same non-integrational episomal
reprogramming vectors as above, and a modified protocol.
Specifically, 106 PBMCs were electroporated with 3 µg of
episomal plasmids (equimolar) using program EO-115 and
solution p3 on the Amaxa 4D nucleofector. Electroporated
PBMCs were transferred into one well of a six-well plate
seeded with MEFs in PBMC recovery medium (RPMI
supplemented with 200 µM 1-thioglycerol (Sigma M6145),
1 µM Dexamethasone (Sigma D1756), 2 U/ml Ery-
thropoietin (R&D Systems 287-TC-500), 100 µg/ml Holo-
transferrin (R&D Systems 2914-HT), 40 ng/ml IGF-1
(Peprotech 100-11), 10 ng/ml IL-3 (Peprotech 200-03),
100 ng/ml SCF (Peprotech 300-07). After 2 days, 2 ml of
PBMC recovery medium was added to transfected cells.
After another 2 days, PBMC recovery medium was replaced
every second day with hESC medium supplemented with
10 ng/ml FGF2. Visible iPSC colonies were mechanically
picked and expanded as per the keratinocyte reprogram-
ming protocol. The iPSCs for the isogenic DS model
included isogenic clones derived from an individual with
DS mosaic for T21 were described by us previously [18]:
D21C3, D21C7, D21C9 and T21C5, T21C6, T21C13.
These were generated by non-integrationally reprogram-
ming primary skin fibroblasts from a person with mosaic
DS, using Sendai virus delivered standard Yamanaka
OKSM factors. The total number of iPSC clones generated
per patient is listed in Table 1. iPSCs were maintained on
Geltrex coated plates and cultured in E8 medium (Life
Technologies) supplemented with penicillin/streptomycin.
Passaging was carried out using ReLESR and 10 μM ROCK
inhibitor was included in culture media for 24 hours after
passaging.
Cerebral organoids
Cerebral organoids were generated following a published
protocol [19] with the following changes. iPSC lines were
first transitioned into feeder free conditions using either
mTESR1 or E8 media with geltrex. To form embryoid
bodies (EBs), hiPSCs were washed once with PBS, then
incubated with Gentle Cell Dissociation Solution (Stemcell
Technologies) for 4 mins. This solution was then removed
and accutase added and incubated for a further 4 mins.
mTESR1/E8 medium at double the volume of accutase
was added to the cells and a single cell suspension gener-
ated by titurating. Cells were centrifuged to remove accu-
tase and then resuspended in hESC medium supplemented
with 4 ng/ml FGF2 and 50micromolar ROCK inhibitor. In
all, 9000 cells were used to form a single EB in each well
using a V-shaped ultra low attachment 96 well plate
(Corning). Specifically, iPSCs were allowed to form EBs in
suspension by culturing for 6 days in hESC medium with
low FGF, in non-adherent culture dishes. After 5–7 days,
EBs were transferred into a 24 well ultra low attachment
plate for neural induction. Neural induction was achieved
by culturing for further 5–7 days in DMEM-F12 supple-
mented with 1% of each: N2, GlutaMAX, and MEM-
NEAA, plus 1 μg/ml heparin. Neurally induced EBs
showing neuroectodermal “clearing” in brightlight micro-
scopy were embedded in matrigel droplets, and transferred
to 6 cm dishes containing organoid differentiation medium-
A, (for 4–5 days), followed by organoid differentiation
medium+A [19]. Organoid maturation was carried out
with 12–16 organoids per 6 cm dish on an orbital shaker at
37 °C, 5% CO2. Aliquots of CM were collected from mature
organoids (100–137 days old from day of EB formation),
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3–4 days after feeding (to allow time for cells to secrete
products into the culture media). Three completely inde-
pendent experiments were carried out each time starting
from undifferentiated iPSC stage, and CM was collected at
3–4 timepoints in each experiment. CM was immediately
frozen and stored at −80 °C.
For inhibitor treatment, organoids were treated from
20DIV (6 days after embedding in matrigel) to 41DIV. βI-
IV and Compound E were added freshly to the media before
use at final concentrations of 2.5 μM and 6 nM, respectively.
Media was replaced every 3–4 days during treatment.
DMSO of the same volume was used as a vehicle only
control.
IP-MS
CM from organoids was analysed by IP-MS, using a pre-
viously described method [20]. The team performing the
MS was blinded to the genotypes in all experiments. In
exp1, all three independent trisomic clones (T21C6, T21C5,
and T21C13) were compared with two independent disomic
clones (D21C3 and D21C7), whereas in exp2, two inde-
pendent trisomic clones (T21C6 and T21C13) were com-
pared with two independent disomic clones (D21C7 and
D21C9).
In exp3, a T21C6 clone was compared with the isogenic
D21C9 clone, and to hiPSC lines from three unrelated
individuals: a DupAPP FEOAD patient (QM-DupAPP), and
two unrelated adult people with DS (QM-DS1 and QM-
DS2).
In all three experiments, IP-MS results for all iPSC lines
that were used in a particular experiment are shown. IP-MS
results were used to calculate the relative ratios of peptides
and these ratios were taken as data points for the statistical
comparisons.
IP-MS spectra were also obtained from the CSF samples
of people with DS and age-matched normal controls. Peak
ratios calculated as described above. The cohorts, methods,
and spectra behind these data were previously described
[22].
FISH
FISH on organoid cryosections was performed as described
[49]. In brief, slides were rinsed in PBS, rehydrated in 10
mM sodium citrate buffer and incubated in the same buffer
at 80 °C for 20 min. Slides were cooled down and incubated
in 2× saline sodium citrate (SSC) for 5 min and in 50%
formamide in 2× SSC for 1 h. After incubation slides were
covered with previously prepared hybridization chamber
and incubated with 10 μL of XA 13/18/21 (D-5607-100-TC,
MetaSystems Probes) Probe, protected from the light, at
45°C for 2 h, at 80 °C for 5 min and for 2 days at 37 °C in
the water bath. Slides were rinsed with 2× SSC at 37 °C
(3 × 15 min) and with 0.12× SSC at 60 °C (2 × 5 min) on the
shaker, equilibrated in 2× SSC at 37 °C for 2 min, coun-
terstained with 4′,6-diamidino-2-phenylindole (DAPI) for
10 min and covered with Dako Fluorescent Mounting
Medium. Fluorescence was captured on Zeiss LSM800
inverted confocal microscope with Airyscan using ×63 oil-
immersed objective. Image analysis was performed using
IMARIS ×64-v9.1.2. Software (BITPLANE, An Oxford
Instruments Co., Zurich, Switzerland). The spots specific
for chromosome 21 were labelled in the red spectrum,
whereas the spots specific for chromosome 13 were labelled
in the green spectrum. More than 500 nuclei from eight
different Z-stacks were evaluated for each clone. Based on
the observed number of fluorescent hybridization signals,
nuclei were assigned to four different categories, namely
“one signal”, “two signals” “three signals” and “>three
signals”. Damaged nuclei or overlapped nuclei with other
nuclei were not included in scoring.
Immunostaining of organoids
Cerebral organoids derived from iPSCs and grown for
indicated number of DIV were fixed in 4% paraformalde-
hyde (PFA), cryoprotected in 30% sucrose/PBS solution
and embedded in OCT. Twenty micron thick sections were
cut and mounted on Superfrost Plus slides (Fisher Scien-
tific) for immunostaining.
For immunofluorescent staining, permeabilisation, and
blocking was carried out in 3% donkey serum with 0.2%
TritonX-100 in PBS for 1 h at room temperature (RT).
Primary antibodies (Supplementary Table 3) were diluted in
1% donkey serum with 0.2% TritonX-100 in PBS and
incubated overnight at 4 °C. Following washes with PBS,
secondary antibodies (Supplementary Table 4) were diluted
in 1% donkey serum with 0.2% TritonX-100 in PBS and
incubated for 2 h at RT. Following washes with PBS, sec-
tions were counterstained with DAPI or DRAQ5 (Supple-
mentary Table 2) for 10 min at RT, washed again and
mounted with DAKO fluorescent mounting medium. As
negative controls for all antibodies, secondary antibody
only controls were carried out (Supplementary Fig. 15).
Western blot
For western blots, whole-cell lysates of iPSCs (Fig. 5c,
Supplementary Fig. 14a) or organoids (Fig. 7o) were
separated in a 10% acrylamide gel by SDS-PAGE and
transferred to a nitrocellulose membrane according to the
manufacturers protocols (Bio-Rad). Following a 60 min
incubation in 5% non-fat milk in TBS-T the membrane
was incubated with primary and secondary antibodies
(Supplementary Tables 3, 4). Quantification was carried
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out using ImageJ software, strictly using the same mem-
branes re-stained using the antibodies shown. For the
protein of interest (BACE2 or TG3), the signal was
adjusted to corresponding β-actin loading control for all
samples. Such adjusted values for unedited/untargeted
cells (n= 4) were set to 1, and used to calculate the fold
change for edited/targeted (n= 4) replicates, and the
resulting fold change values for pairs run on the same gel
were averaged and analysed by student’s t test. Membrane
stripping between stainings was carried out using
Thermo-Fisher stripping solution, following manu-
facturer’s instructions.
AmyloGlo and Thioflavine S staining
For AmyloGlo staining, OCT embedded slices were rinsed
with PBS, and incubated in 70% ethanol for 5 min at RT,
followed by washing with milli Q water for 2 min at RT.
Slices were then incubated with AmyloGlo solution for 10
min in the dark at RT, followed by washing in 0.9% saline
solution for 5 min at RT, and counterstaining with DRAQ5
for 10 min at RT. Thioflavine S staining was performed as
described [50]. OCT embedded slices were rinsed with PBS
and incubated with Thioflavine S solution for 10 min in the
dark at RT, differentiated in 80% ethanol and counter-
stained with DRAQ5 for 10 min at RT, rinsed with PBS and
mounted with DAKO fluorescent mounting medium.
Formic acid pre-treatment
To increase signal of insoluble β-amyloid material
T21C5Δ7 (96DIV) organoid slices were treated with 87%
Formic acid for 10 min at RT. After 10 min formic acid
was rinsed three times with PBS and samples were immu-
nostained as described above.
Human brain samples
PFA-fixed, paraffin-embedded human anonymized post-
mortem brain samples were obtained from the Brain Bank
of the Croatian Institute for Brain Research (CIBR), Insti-
tute of Pathology of The Royal London Hospital (IP-RLH)
and the South West Dementia Brain Bank (UK) (Supple-
mentary Table 1). Slices were cut at 5–10 μm thickness, and
stained using primary antibodies, secondary fluorophore-
coupled anti-Ig antibodies and their respective dilutions
(Supplementary Tables 3, 4).
Immunohistochemistry and immunofluorescence on
human brain tissue
PFA-fixed, paraffin-embedded 5–10 μm thick slides were
de-paraffinised by incubation in xylene, rehydrated in a
graded series of ethanol and rinsed in PBS for 10 min. For
antigen retrieval, the slides were steamed in 0.01 M citrate
buffer, pH 6.0 at 100 °C for 30 min, cooled and rinsed 3 ×
10 min in PBS. On slides used for IHC, endogenous per-
oxidases were quenched with 0.025% hydrogen peroxide
for 30 min at RT and rinsed 3 × 10 min in PBS. Double
immunohistochemical staining was performed “Polink DS-
MR-Hu A2 Kit for Immunohistochemistry Staining” (GBI
Labs, DS202A-18). In brief, Polymer-HRP and AP Double
staining kit distinctly labels two different antigens in human
tissue, using mouse (GBI-Permanent Red) and rabbit
(DAB-brown) antibodies. Single IHC was performed
“VECTASTAIN ABC HRP Kit”. For immunofluorescence,
following antigen retrieval, slides were incubated in
blocking/permeabilisation solution (0.2% Triton X-100 in
PBS + 3% donkey serum) for 1 h at RT. The slides were
incubated over night at 4 °C with primary antibodies
(Supplementary Table 3) in solution (0.2% Triton X-100 in
PBS+ 1% donkey serum). Next day primary antibodies
were rinsed 3 × 5 min in PBS and incubated for 2 h with
secondary antibodies (Supplementary Table 4) in 0.2%
Triton X-100 in PBS at RT and rinsed 3 × 5 min in PBS.
Nuclei were counterstained with DAPI for 10 min, rinsed
3 × 5 min in PBS and mounted with Dako Fluorescent
Mounting Medium. In order to distinguish the contribution
of lipofuscin autofluorescence to the colocalised signals,
specificity of primary antibodies (Aβx-34 and BACE2) has
been validated using three different methods: Sudan black B
staining (Supplementary Fig. 8a), pre-incubation with
BACE2 specific immunogenic peptide (Supplementary
Fig. 8b–e) and Lambda (λ) scan function on confocal
microscope (Supplementary Fig. 8f, g). Three different
samples (DS-AD1, DS (28 yrs) pre-AD and euploid spora-
dic AD (73 yrs) after IHC were stained with 0.1% Sudan
black B in 70% ethanol for 20 min at RT and analysed on
confocal microscope with Airyscan. Sample DS-AD1 was
stained with antibodies solution, 12 h pre-absorbed with
BACE2 specific immunogenic peptide, and analysed on
confocal microscope and slide scanner. Lambda scan
records a series of individual images within a defined
wavelength range (in our case from 630 nm to end of
spectrum) and each image was detected at a specific emis-
sion wavelength, at 10 nm intervals. For lambda scan ana-
lysis, samples were stained with one primary antibody and
labelled with far-red secondary antibody (647). As negative
control, we used secondary antibody (647) alone and, as
additional negative control, one sample was counterstained
with DAPI only, without secondary antibody. As we used a
far-red (647) antibody, we analysed expression from 630
nm to the end of spectrum at 10 nm intervals. Aβx-34 and
BACE2 antibodies showed specific peaks, significantly
over and above the autofluorescent signal, in all three spe-
cific ROI indicated in Fig. 4 and Supplementary Fig. 8
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(intraneuronal fine-vesicles, large intraneuronal spherical
granules and extracellular aggregates). DAPI and secondary
antibody alone show peaks only at background level.
Samples were analysed by: LSM800 Inverted Confocal
Microscope with Airyscan (ZEISS), LSM800 Upright
Confocal Microscope (ZEISS), LEICA DM6000 CFS, and
Axioscan.Z1 Slide Scanner (ZEISS). As negative controls
for all antibodies, secondary antibody only controls were
carried out (Supplementary Fig. 8h).
Gallyas staining
For Gallyas staining samples were depariffinised and/or
rinsed in PBS, then treated with Ammonium-Silver Nitrate
(0.1 g NH4NO3, 0.1 g AgNO3, 0.3 mL 4% NaOH) solution
for 30 min protected from the light, rinsed with 0.5% acetic
acid (3 × 3 min) and placed in developer solution for 5–30
min. Developer solution was made from three stock solu-
tions: 25 ml of Solution A (50 g Na2CO3+ 1000 mL dis-
tilled water), 7.5 ml of Solution B (2 g NH4NO3+ 2 g
AgNO3+ 10 g Tungstosalicic acid hydrate + 1000 mL
distilled water) and 17.5 ml of Solution C (2 g NH4NO3+ 2
g AgNO3+ 10 g Tungstosalicic acid hydrate + 7.3 ml 37%
formaldehyde solution +1000 mL distilled water). After
developer solution samples were rinsed in water and placed
in destaining solution (30 g K2CO3+ 55 g EDTA-Na2+ 25
g FeCl3+ 120 g Na2S2O3+ 20 g KBr +1000 mL distilled
water). Finally, samples were rinsed two times in 0.5%
acetic acid. After staining samples were rinsed in water,
dehydrated in a graded series of ethanol, cleared in Histo-
Clear and mounted with Histomount mounting medium.
Samples were scanned by NanoZoomer 2.0RS
(HAMAMATSU).
Image analysis
Immunofluorescent stains of 20 µm thick slices are shown
as maximal projections captured on Zeiss LSM800 upright
confocal microscope using ×63 oil-immersed objective.
Image analysis was performed using IMARIS x64-v9.3.1.
Software (BITPLANE, An Oxford Instruments Co., Zurich,
Switzerland). Quantification was performed blinded to the
genotype, on five independent images representing three
individual organoids per genotype, and containing
3000–4000 cells per image. Only images within the “cor-
tical” part of the organoid were considered for analysis. For
quantification of protein/peptide markers, total fluorescence
intensity of positive signals for each wavelength for a given
antibody was normalised to the total fluorescence intensity
for MAP2 as a pan-neuronal marker.
For colocalisation calculations: image analysis was per-
formed using IMARIS software. Pairwise Pearson’s coef-
ficient of colocalised volume for a pair of co-stained
antibodies with contrasting fluorescence wavelengths was
automatically calculated by the IMARIS software on 3–8
images from three independent organoids, per any given
antibody combination, using a maximal projection through
the entire z-stack.
A new FRET-assay for the detection of AβDP activity
generating Aβ1-34
We designed and synthesized a new FRET-based peptide
containing the fluorophore at one end and the quencher at
the other end, and spanning the Aβ34 site in its middle. The
exact peptide design is under discussion for intellectual
property protection. The FRET (BACE2 R&D Systems, not
based on amyloid sequence) control peptide (10 µM) (not
shown) or the newly designed FRET Aβ34 site peptide (10
µM) were digested at 37 °C by human BACE2 (R&D sys-
tems, 1 ng/µL) in presence or absence of the stated inhibi-
tors for 2 h. Three replicates per inhibitor per concentration
were used. Enzyme activity was defined by measuring the
fluorescence increase before and after the incubation. After
blank-subtracted fluorescence units were normalized to the
control digest, one-way analysis of variance (ANOVA) was
performed. P values were calculated with a post hoc Bon-
ferroni correction for multiple comparisons (only pairs
relative to the untreated control were simultaneously com-
pared). Error bars represent standard error.
Statistical analysis
Initial analysis was carried out using Microsoft Excel to
calculate two-tailed student t tests. Additional
Holm–Bonferroni correction was carried out using the
Excel macro from ref. [51]. For all multiple comparison
analysis, ANOVA and Holm–Bonferroni calculations were
performed at http://astatsa.com/OneWay_Anova_with_
TukeyHSD/, or using GraphPad Prism 8.4.1 software.
SNP arrays
iPSC lines genome integrity: genomic DNA was isolated
from iPSCs using standard column kits. DNA of all iPSC
lines shown in the manuscript were re-analysed at the
similar passage used for the derivation of organoids using
SNP arrays Illumina OmniExpress v1.1 chips and analysis
performed in Genome Studio 2.0 software. Following
CRISPR editing, T21C5Δ7 was assessed by SNP array and
no genomic alternations were detected compared with the
parental C5 iPSC clone. See the raw data from this for
chromosome 21 array, the rest are not shown for the lack of
space, data available on request). The genome integrity of
the isogenic iPSC clones was previously published [18] (but
was repeated here as described above). No additional
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rearrangements owing to re-programming or passaging
were observed.
The cohort of people with DS has been described in
recent reports [52, 53]. In brief, participants donated DNA
samples and had detailed cognitive and clinical assessments
to determine dementia status [54]. Age of dementia diag-
nosis was established and shown in Table 1. Genotyping
was done in the UCL Genomics Centre using Human
OmniExpressExome v1.2,v1.3,v1.4 beadchips. SNP clus-
tering and genotyping, was undertaken using GenomeStu-
dio (Illumina, San Diego, CA, USA). Manual reclustering






Quantitative paralogous amplification-pyrosequencing was
carried out based on the published method [55]. This
method takes advantage of the existence of identical
sequences on chromosome 21 and one other autosome,
allowing amplification of both loci with a single primer pair.
Paralogous sequence mismatches in amplified products
from chromosome 21 (GABPA and ITSN) can be quantified
relative to their paralogous regions on chromosome 7 and 5,
respectively. As such, trisomic cells show a 60:40 ratio for
the paralogous sequence, whereas disomic cells produce a
50:50 ratio. Primers used for amplification and pyr-
osequencing are listed in Supplementary Table 5. Pyr-
osequencing was performed on the Pyromark Q48 machine
(Qiagen) following standard procedures.
CRISPR/SpCas9-HF1 editing of the BACE2 locus
The guide-RNA (gRNA) targeting BACE2 Exon 3 was
cloned into a vector containing the high fidelity SpCas9-
HF1 [56] and blasticidin S resistance gene. The complete
plasmid was delivered via Lipofectamine3000 to a trisomic
iPSC clone T21C5 (full official name NIZEDSM1iT21-C5),
which was described and characterized in a previous report
[18]. Untransfected iPSCs were removed by treatment with
blasticidin (2 μg/ml for 48 h). Individual colonies were
picked and further sub cloned by limiting dilution to
achieve clonal cell lines. DNA was purified from individual
clones, PCR amplified and sequenced by Sanger Sequen-
cing. Sequences were analysed in Mutation Surveyor
(V3.1.0) and “Tracking InDels by dEcomposition (TIDE)”
(TIDE V 2.0.1, Desktop Genetics). TIDE analysis of the
CRISPR-targeted clone 2.3.5 DNA sequence gave a score
of 65% of the wt read remaining (not shown). The quality of
the gRNA was assessed using two different prediction
software platforms: CCTop online software [57], and the
MIT online platform (http://crispr.mit.edu/). The same two
software platforms were used to predict the off-target sites.
Neither platform found any off-targets with 0, 1, or 2
mismatches. The top 10 CCTop-predicted sites were PCR
amplified in both Δ7 and WT clones, then sequenced by
Sanger Sequencing to rule out off-target events. No differ-
ences in the sequence were found.
shRNA targeting of BACE2 in iPSCs
One day after plating, small colonies of feeder free iPSCs
were transduced with lentiviral shRNA particles targeting
BACE2 (sc-29776) or a non-targeting control (sc-108080).
Lentiviral particles were obtained from Santa Cruz Bio-
technology Inc. The lentiviral particles for BACE2 contain
three different shRNAs targeting human BACE2. In total,
5000 infectious units (IFU) of virus were added per 12-well,
and incubated overnight. The following day, viral media
was removed and replaced with fresh media. Four days after
transduction, stably transduced cells were selected by
treatment with 0.5 μg/ml puromycin for 14 days, passaging
as required. Following this, iPSCs were maintained in 0.3
μg/ml puromycin. Knockdown of BACE2 was confirmed
by western blot (Supplementary Fig. 14a).
Protein isolation from cortical organoids
Organoids were collected at specified durations in culture
(expressed as DIV) and washed twice with ice-cold PBS.
The samples were resuspended in ice-cold NP-40 Buffer
(150 mM NaCl, 1% NP-40, 50 mM Tris pH8) containing
EDTA free protease inhibitors (complete cocktail, Roche)
and lysed using a 1 ml tissue homogenizer (Fisher). Each
sample was centrifuged at 10,000 rpm for 10 minutes at
4 °C and the homogenates were stored at −80 °C. Protein
concentration was determined using the bicinchoninic acid
method (Pierce).
Detection of fibrillary material from organoids by
transmission electron microscopy (TEM)
Organoids were lysed following the same procedure for
protein extraction, however, samples were initially spun at
20,000 × g for 20 minutes at 4 °C. Following the first cen-
trifugation, supernatants were removed and kept on ice. The
remaining cell pellets were resuspended in 5× weight/
volume buffer (10 mM Tris-HCL pH7.5, 0.8 M NaCl, and
10% sucrose) [58] containing proteases inhibitor and spun
at 20,000 × g for 20 minutes at 4 °C. An equal volume of
supernatant 1 was added to the supernatant from the second
centrifugation step. 1% N-lauroysarcosinate (weight/
volume) was added and the samples were rocked at RT for
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1 hour. The samples were ultra-centrifuged at 100,000 × g
for 1 hour at 4 °C. The supernatant was decanted and the
sarkosyl-insoluble pellet was resuspended in ice-cold PBS
prior to imaging. The samples were deposited on to glow-
discharged 400 mesh formvar/carbon film-coated copper
grids, negatively stained with a 2% aqueous (w/v) uranyl
acetate solution and then immediately analysed at 100 kV
using a JEOL TEM1010 equipped with a Gatan Orius
camera.
TEM analysis of synthetic Aβ1–40 fibrils in vitro
Synthetic Aβ peptide powder (China peptides) was treated
with 1,1,1,3,3,3-hexafluoro-2-propanol and lyophilized.
The peptide was then dissolved in 20 µL of 100 mM NaOH
and then diluted with buffer. A 50 µM stock of this mono-
meric Aβ peptide was grown at 37 °C shaking at 180 rpm
for 48–60 hours before recording the TEM images. In all, 4
µL of extract was added to a 15 nm thick, lacey carbon on
300 mesh grid (glow-discharged) for 2 minutes followed by
negative staining with 2% uranyl acetate for 1 minute and
then air dried. The grids were then viewed under FEI T12,
120 kV Transmission electron microscope equipped with a
4 K CCD camera (FEI) at ×30,000 magnification under low-
dose conditions.
Data availability
All data that support the findings described in this study are
available within the manuscript and the related supple-
mentary information, and from the corresponding authors
upon reasonable request.
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